Spotlight on Pediatrics
Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge
StartActivity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of ADHD symptoms on functional abilities and quality of life.
- Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
- Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
- Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.
Activity Description
Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.
Activity Chair
Founder and Director
Attention MD
Grand Rapids, MI
Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care
Companion for CNS Diseases
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to:
0.5 Medical Knowledge MOC points in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program; and
0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM or ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME
credits claimed for the activity.
The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
12/31/2020 to 12/30/2021. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse practitioners participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA
PRA Category 1 Credit(s)™ from organizations accredited by
Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME. Physician
assistants may receive a maximum of 0.5 hours credit for completing this
program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of ADHD symptoms on functional abilities and quality of life.
- Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
- Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
- Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.
Activity Description
Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.
Activity Chair
Founder and Director
Attention MD
Grand Rapids, MI
Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care
Companion for CNS Diseases
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to:
- 0.5 Medical Knowledge MOC points in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program; and
0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM or ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME
credits claimed for the activity.
The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
12/31/2020 to 12/30/2021. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse practitioners participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA
PRA Category 1 Credit(s)™ from organizations accredited by
Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME. Physician
assistants may receive a maximum of 0.5 hours credit for completing this
program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Pediatrics Presentations
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment
StartActivity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Expires: October 17, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.5 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
StartActivity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis
StartActivity Details
Expires: June 4, 2022
Accredited By
Target Audience
This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Identify patients with EoE using the latest diagnostic recommendations and criteria
- Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
- Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
- Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
- Indicate the potential roles of investigational treatments in EoE management plans
Activity Description
Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.
Faculty discussion will focus on:
- Recognizing and diagnosing EoE
- Treating EoE as a chronic disease
- Novel developments in treatment
Statement of Educational Need
EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.
Agenda
Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic
Treatment of EoE
Faculty
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen,
Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers
Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel,
Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner,
Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage,
Miraca, Nutricia, Regeneron, Shire/Takeda
Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose
Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics,
Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb,
Interpace, Lucid, Regeneron, Shire/Takeda
Calies Menard-Katcher, MD, MSCS
Nothing to disclose
Robert Pesek, MD
Nothing to disclose
Conflict of Interest Policy/Disclosure Statement
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE
Contact Information for Questions About the Activity
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
Activity Details
Expires: June 4, 2022
Accredited By
Target Audience
This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Identify patients with EoE using the latest diagnostic recommendations and criteria
- Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
- Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
- Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
- Indicate the potential roles of investigational treatments in EoE management plans
Activity Description
Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.
Faculty discussion will focus on:
- Recognizing and diagnosing EoE
- Treating EoE as a chronic disease
- Novel developments in treatment
Statement of Educational Need
EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.
Agenda
Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic
Treatment of EoE
Faculty
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen,
Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers
Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel,
Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner,
Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage,
Miraca, Nutricia, Regeneron, Shire/Takeda
Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose
Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics,
Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb,
Interpace, Lucid, Regeneron, Shire/Takeda
Calies Menard-Katcher, MD, MSCS
Nothing to disclose
Robert Pesek, MD
Nothing to disclose
Conflict of Interest Policy/Disclosure Statement
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE
Contact Information for Questions About the Activity
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
Research Updates in Gout: Improving Response Rate to Therapy
StartActivity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
Activity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices
StartActivity Details
AAPA Category 1 CME credit(s)
Expires: January 7, 2022
Accredited By
Jointly Provided By
Target Audience
This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.
Learning Objectives
- Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
- Outline risks associated with delayed intervention in patients with diabetic eye disease.
- Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
- Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.
Activity Description
This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.
Statement of Educational Need
The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.
The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1
With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.
1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.
2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682
3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009
Agenda
- Latino/Hispanic population growth in the US
- Healthcare disparities
- Diabetic eye disease risk and complications
- Eye exam frequency recommendations
- Triage and other practical diagnostic challenges
- Screening and exam recommendations
- Evidence-based best practices for diagnosing diabetic eye disease
- The most commonly performed procedure in ophthalmology
- Anti-VEGF treatments for DME
- Anti-VEGF treatments for DR
- Anti-VEGF treatments for NPDR
Faculty
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Conflict of Interest Policy/Disclosure Statement
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.
Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.
The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.
Instructions for Receiving Credit
A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.
Statement of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com
Activity Details
AAPA Category 1 CME credit(s)
Expires: January 7, 2022
Accredited By
Jointly Provided By
Target Audience
This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.
Learning Objectives
- Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
- Outline risks associated with delayed intervention in patients with diabetic eye disease.
- Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
- Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.
Activity Description
This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.
Statement of Educational Need
The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.
The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1
With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.
1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.
2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682
3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009
Agenda
- Latino/Hispanic population growth in the US
- Healthcare disparities
- Diabetic eye disease risk and complications
- Eye exam frequency recommendations
- Triage and other practical diagnostic challenges
- Screening and exam recommendations
- Evidence-based best practices for diagnosing diabetic eye disease
- The most commonly performed procedure in ophthalmology
- Anti-VEGF treatments for DME
- Anti-VEGF treatments for DR
- Anti-VEGF treatments for NPDR
Faculty
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Conflict of Interest Policy/Disclosure Statement
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.
Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.
The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.
Instructions for Receiving Credit
A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.
Statement of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com
Complicating Factors in Pediatric Rheumatology: Managing Influenza
StartActivity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
- Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.
Activity Description
Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.
Agenda
Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Treating Influenza in Pediatric Patients With Rheumatic
Disease
Stan L. Block, MD, FAAP
Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy,
MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Activity Chair
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL
Disclosure:
Consulting Fee: Novartis, UCB
Faculty
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY
Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA
Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the learner to earn up to 1.25 MOC points in the American Board of
Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME
activity provider’s responsibility to submit learner completion information
to ACCME for the purpose of granting ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
- Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.
Activity Description
Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.
Agenda
Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Treating Influenza in Pediatric Patients With Rheumatic
Disease
Stan L. Block, MD, FAAP
Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy,
MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Activity Chair
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL
Disclosure:
Consulting Fee: Novartis, UCB
Faculty
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY
Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA
Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the learner to earn up to 1.25 MOC points in the American Board of
Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME
activity provider’s responsibility to submit learner completion information
to ACCME for the purpose of granting ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge
StartActivity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of ADHD symptoms on functional abilities and quality of life.
- Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
- Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
- Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.
Activity Description
Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.
Activity Chair
Founder and Director
Attention MD
Grand Rapids, MI
Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care
Companion for CNS Diseases
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to:
- 0.5 Medical Knowledge MOC points in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program; and
0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM or ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME
credits claimed for the activity.
The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
12/31/2020 to 12/30/2021. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse practitioners participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA
PRA Category 1 Credit(s)™ from organizations accredited by
Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME. Physician
assistants may receive a maximum of 0.5 hours credit for completing this
program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: December 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of ADHD symptoms on functional abilities and quality of life.
- Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
- Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
- Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.
Activity Description
Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.
Activity Chair
Founder and Director
Attention MD
Grand Rapids, MI
Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care
Companion for CNS Diseases
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to:
- 0.5 Medical Knowledge MOC points in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program; and
0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM or ABP MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME
credits claimed for the activity.
The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A
Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring
Materials, Self-Study AAFP Prescribed credit. Term of Approval is from
12/31/2020 to 12/30/2021. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurse practitioners participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA
PRA Category 1 Credit(s)™ from organizations accredited by
Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for
AMA PRA Category 1 Credit(s)™ through the American Academy of
Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1
Credit(s)™ from organizations accredited by the ACCME. Physician
assistants may receive a maximum of 0.5 hours credit for completing this
program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV
StartActivity Details
Expires: November 12, 2021
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Target Audience
The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).
Learning Objectives
After completing this activity, the participant should be better able to:
- Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care
Activity Description
This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.
Statement of Educational Need
Depression is common in patients with HIV and can result in nonadherence
and reduced levels of viral suppression.1,2 Clinicians should be
aware of the relationship between stigma, social isolation, and depression,
which may be particularly severe in people of color and men who have sex with
men (MSM).3 Pharmacologic treatment of depression can greatly
improve quality of life, adherence, and, therefore, viral suppression.
Depression is not the only factor that may affect a patient’s mental
health. Substance use disorder, or even recreational substance use, which is
not uncommon in the HIV population, like depression, may result in reduced
adherence or viral suppression.4,5 Patients should be screened in
a nonjudgmental manner so that they may be referred to addiction programs or
mental health professionals.6 Through a peer-to-peer discussion,
Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV
specialist can use to screen for and address both mental health disorders and
substance use in patients with HIV.
- Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
- Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS. 2017;31(18):2515-2524.
- Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
- Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
- Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
- US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Global Contact Information
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
Expires: November 12, 2021
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Target Audience
The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).
Learning Objectives
After completing this activity, the participant should be better able to:
- Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care
Activity Description
This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.
Statement of Educational Need
Depression is common in patients with HIV and can result in nonadherence
and reduced levels of viral suppression.1,2 Clinicians should be
aware of the relationship between stigma, social isolation, and depression,
which may be particularly severe in people of color and men who have sex with
men (MSM).3 Pharmacologic treatment of depression can greatly
improve quality of life, adherence, and, therefore, viral suppression.
Depression is not the only factor that may affect a patient’s mental
health. Substance use disorder, or even recreational substance use, which is
not uncommon in the HIV population, like depression, may result in reduced
adherence or viral suppression.4,5 Patients should be screened in
a nonjudgmental manner so that they may be referred to addiction programs or
mental health professionals.6 Through a peer-to-peer discussion,
Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV
specialist can use to screen for and address both mental health disorders and
substance use in patients with HIV.
- Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
- Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS. 2017;31(18):2515-2524.
- Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
- Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
- Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
- US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Global Contact Information
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Influenza in the Hospital: Perils and Pearls
StartActivity Details
ABIM MOC
Expires: November 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hospitalists and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Incorporate evidence-based guidelines and best practices to diagnose influenza early.
- Differentiate antiviral agents based on their efficacy and ability to reduce viral shedding and transmission of influenza.
- Select treatment for patients presenting with suspected influenza based on patient symptoms, history and characteristics, and comorbidities, to reduce complications in those who are at normal or at high risk.
- Review the use of prophylaxis in patients who are exposed to influenza and who are at normal, or at high risk for complications.
Activity Description
Influenza places a substantial burden every year on the health of people in the United States. Most hospitalizations and deaths occur in patients who are at high risk for developing complications, including immunocompromised individuals and those with comorbidities. Timely diagnosis and management of influenza in the hospital setting poses unique challenges. Clinicians treating influenza in the hospital setting must be able to differentiate available antiviral therapies based on their safety, efficacy, and ability to reduce viral shedding. In this educational program, experts will review the latest evidence on antiviral agents for treatment and prophylaxis of influenza. Using case-based examples, faculty will discuss strategies for timely diagnosis and initiation of the most appropriate treatment regimen to reduce morbidity and mortality in patients with influenza in the hospital setting.
Agenda
Introduction
Christopher S. Kim, MD, MBA, SFHM
Influenza: Having a Keen Eye for Details to Improve
Diagnosis
Christopher S. Kim, MD, MBA, SFHM
Case Presentation: Patient With Suspected Flu But Lacking Classic
Symptoms
Christopher S. Kim, MD, MBA, SFHM
Treating Influenza: Applying New Evidence to Hospital
Medicine
Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentation: Patient With Influenza at High Risk for
Complications
Paul G. Auwaerter, MD, MBA, FIDSA
Activity Chair
Associate Professor
General Internal Medicine
Associate Medical Director
University of Washington Medical Center
Seattle, WA
Disclosures:
No relevant financial relationships to disclose.
Faculty
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures:
Consulting Fee: Advanced Biotherapeutics, DiaSorin
Ownership Interest: Johnson & Johnson
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 1.25 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Participants who successfully complete the program and opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
ABIM MOC
Expires: November 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hospitalists and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Incorporate evidence-based guidelines and best practices to diagnose influenza early.
- Differentiate antiviral agents based on their efficacy and ability to reduce viral shedding and transmission of influenza.
- Select treatment for patients presenting with suspected influenza based on patient symptoms, history and characteristics, and comorbidities, to reduce complications in those who are at normal or at high risk.
- Review the use of prophylaxis in patients who are exposed to influenza and who are at normal, or at high risk for complications.
Activity Description
Influenza places a substantial burden every year on the health of people in the United States. Most hospitalizations and deaths occur in patients who are at high risk for developing complications, including immunocompromised individuals and those with comorbidities. Timely diagnosis and management of influenza in the hospital setting poses unique challenges. Clinicians treating influenza in the hospital setting must be able to differentiate available antiviral therapies based on their safety, efficacy, and ability to reduce viral shedding. In this educational program, experts will review the latest evidence on antiviral agents for treatment and prophylaxis of influenza. Using case-based examples, faculty will discuss strategies for timely diagnosis and initiation of the most appropriate treatment regimen to reduce morbidity and mortality in patients with influenza in the hospital setting.
Agenda
Introduction
Christopher S. Kim, MD, MBA, SFHM
Influenza: Having a Keen Eye for Details to Improve
Diagnosis
Christopher S. Kim, MD, MBA, SFHM
Case Presentation: Patient With Suspected Flu But Lacking Classic
Symptoms
Christopher S. Kim, MD, MBA, SFHM
Treating Influenza: Applying New Evidence to Hospital
Medicine
Paul G. Auwaerter, MD, MBA, FIDSA
Case Presentation: Patient With Influenza at High Risk for
Complications
Paul G. Auwaerter, MD, MBA, FIDSA
Activity Chair
Associate Professor
General Internal Medicine
Associate Medical Director
University of Washington Medical Center
Seattle, WA
Disclosures:
No relevant financial relationships to disclose.
Faculty
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures:
Consulting Fee: Advanced Biotherapeutics, DiaSorin
Ownership Interest: Johnson & Johnson
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 1.25 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Participants who successfully complete the program and opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Chronic Idiopathic Urticaria Curbside Consults ̶ Re-thinking the Burden of Chronic Idiopathic Urticaria: Assessing the Quality of Life
StartActivity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work, and activity.
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Khan discuss the burden of CIU/CSU and its impact on patient quality of life (QoL), including disease-specific measures for assessing QoL and strategies for selecting the best treatment to minimize disease burden.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine and Pediatrics
Allergy & Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosure:
Consulting Fee: Aimmune
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: November 22, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.
Learning Objective
Upon successful completion of the activity, participants should be better able to assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work, and activity.
Activity Description
Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Khan discuss the burden of CIU/CSU and its impact on patient quality of life (QoL), including disease-specific measures for assessing QoL and strategies for selecting the best treatment to minimize disease burden.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda
Faculty
Professor of Medicine and Pediatrics
Allergy & Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosure:
Consulting Fee: Aimmune
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com